Hemoglobinopathies Market by Product Type, Distribution Channel, End User 2023-2028

Report DescriptionAbout IMARC Group

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Global Hemoglobinopathies Market Research Report:

The latest report by IMARC, titled “ HemoglobinopathiesMarket:GlobalIndustryTrends,Share,Size,Growth,OpportunityandForecast 2023-2028

” the global hemoglobinopathies market size reached US$ 9.2 Billion in 2022.

Hemoglobinopathies are genetic disorders that cause abnormalities in the structure and production of hemoglobin molecules and are passed from parents to children. These disorders result from differences in the structure and synthesis of hemoglobin, which include a variety of congenital blood ailments. As a result, one of the globin chains of the hemoglobin molecule develops an abnormal structure, preventing it from carrying oxygen through the body and resulting in anemia.

The most common symptoms of hemoglobinopathies are pale skin, shortness of breath, cold hands or feet, fatigue, pain and swelling. This disease is associated with numerous health problems, such as blurry vision, heart problems, slowed growth, gallstones, enlargement of the spleen, and strokes.

Request Free Sample Report: https://www.imarcgroup.com/hemoglobinopathies-market/requestsample

Report Description Report Description and Highlights

Global Hemoglobinopathies Market Trends:

The global market is majorly driven by the rising prevalence of various chronic blood disorders, including sickle cell disease (SCD) and thalassemia and anemia. This can be attributed to the growing geriatric population that is prone to developing various chronic illnesses. In addition to this, the widespread adoption of cost-effective genetic testing, usage of gene therapy and the approval of novel therapies are also creating a positive market outlook. The market is further impelled by partnerships and collaborations among major biopharmaceutical players using the latest technology platforms.

Apart from this, multiple favorable initiatives, including thalassemia screening in neonates and improved reimbursement scenarios for diagnostic tests and treatments, undertaken by the governments of several countries are impacting the market positively. Some of the other factors contributing to the market include continual developments in point-of-care diagnostics, a considerable rise in medical expenditure and extensive research and development (R&D) activities. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 16.3 Billion by 2028, exhibiting a CAGR of 9.39% during 2023-2028.

Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).

Report Description Report Description and Highlights

MarketSummary:

BreakupbyType:

• Thalassemia

• Alpha Thalassemia

• Beta Thalassemia

• Sickle Cell Disease

• Others

BreakupbyTreatment:

• Blood Transfusion

• Stem-cell Transplantation

• Analgesics

• Antibiotics

• ACE Inhibitors

• Hydroxyurea

• Others

BreakupbyTestType:

Report Description Report Description and Highlights

• Red Blood Cell (RBC) Count

• Genetic Testing

• High Performance Liquid Chromatography (HPLC)

• Hemoglobin Isoelectric Focusing (Hb IEF)

• Hemoglobin Electrophoresis (Hb ELP)

• Hemoglobin Solubility Test

BreakupbyEndUser:

• Hospitals and Clinics

• Diagnostics Laboratories

• Others

BreakupbyRegion:

• North America

• United States

• Canada

• Asia-Pacific

• China

• Japan

• India

• South Korea

• Australia

• Indonesia

• Others

• Europe

• Germany

• France

• United Kingdom

• Italy

• Spain

• Russia

• Others

• Latin America

• Brazil

• Mexico

• Others

• Middle East and Africa

Report Description Report Description and Highlights

CompetitiveLandscapewithKeyPlayers:

• Bio-Rad Laboratories Inc

• bluebird bio Inc.

• Bristol-Myers Squibb Company

• Danaher Corporation

• Emmaus Life Sciences Inc.

• Gamida-Cell Ltd.

• Global Blood Therapeutics Inc.

• Novartis AG

• PerkinElmer Inc.

• Pfizer Inc.

• Prolong Pharmaceuticals LLC

• Sangamo Therapeutics Inc.

• Sysmex Corporation.

ViewFullReportwithTOC&ListofFigure:

https://www.imarcgroup.com/hemoglobinopathies-market

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

A partial List of our Clients

Partial List of Clients

We are the trusted business partners to the world's leading corporates, governments, and institutions

Report Description Report Description and Highlights

© 2019 IMARC All Rights Reserved

This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.